iCAN:Israel-Cannabis has partnered with respiratory devices maker Aura Medical to offer the US Food and Drug Administration (FDA) approved nebulisers for delivery of medical cannabis.
Aura’s Nebican Portable Nebuliser is developed for use as part of the treatment for asthma and chronic obstructive pulmonary disease (COPD).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The portable and easy-to-use device is designed using Vibrating Mesh Technology (VMT) and utilises specially formulated controlled dosages.
Nebican is said to use atomisation to deliver thin, fog-like mist that could easily penetrate into the lungs.
Aura Medical CEO Connie Lefkowitz said: “We are proud to pair our unique delivery platform, that, until now, has been used for prescription medications, including Albuterol, Pulmicort Respules, DuoNeb Intal and others, with targeted formulation from Ci Therapeutics.”
Ci Therapeutics, which was established as a joint venture between iCAN and CannRX, is a cannabis company that has been validating ican.sleep cannaceutical for delivery through Nebican.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe firms intend to launch both Nebican and ican.sleep mid-next year in California, US, with plans to expand into Canada.
iCAN:Israel-Cannabis founder and CEO Saul Kaye said: “This is a game changer, taking an advanced pulmonary FDA-approved delivery platform and formulating a sleep product to deliver safe cannabis in a doseable and repeatable way.”
Ci Therapeutics focuses on offering a platform for advanced, clinically validated formulations on pharmaceutical grade delivery systems.
CannRx develops quantitative and qualitative analytical chemical assays and disease-specific bioassays to identify specific cannabinoid activity in the cannabis plant.
